+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are studying the use of LSALT peptide to prevent or reduce acute kidney injury AKI in patients undergoing on-pump cardiac surgery. This trial evaluates how often AKI occurs within 7 days after such surgery, using established kidney function criteria. The study is a randomized, double-blind, placebo-controlled Phase 2 trial involving patients at risk of AKI due to their kidney function or other health factors. Participants will be randomly assigned to receive either the LSALT peptide or a placebo. The LSALT peptide is given intravenously at 10 mg over one hour twice daily for five days, starting at least one hour before anesthesia begins. The placebo group receives a matching saline solution on the same schedule. Standard care continues alongside the study treatments, and safety is closely monitored by an independent board. Throughout the study, participants will have daily physical exams, vital sign checks, and urine output monitoring during the treatment period and shortly after. Kidney function tests and biomarker assessments occur at baseline and regularly through 28 days after surgery. Adverse events are recorded daily during treatment and on follow-up days. The study tracks kidney injury severity, need for kidney replacement therapy, mortality, hospital stay length, and other health outcomes to understand the treatments effects.

Age: 18Years +All GendersPhase 2
9 locations
S

Actively Recruiting

Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.

Age: 18Years +All Genders
69 locations